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A computationally assisted approach has enabled the ﬁrst
catemeric polymorph of carbamazepine (form V) to be
selectively formed by templating the growth of carbamazepine
from the vapour phase onto the surface of a crystal of dihydro-
carbamazepine form II.
Why are more polymorphs of organic molecules predicted
than are observed experimentally?1,2 Either predictive
methods overestimate the true potential for polymorphism
or experimental polymorph screens do not sample the
appropriate nucleation and growth conditions required to
encounter all forms. This question is of particular signiﬁcance
given the importance of controlling solid-state structure in
many chemical industries, either as a means of optimizing a
material’s properties3 or to prevent the unexpected appearance
of a new form during the development of a production
process.4 A considerable challenge therefore is to improve
upon established approaches to solid form discovery5–7 to
select a speciﬁc desired crystal structure from the predicted
crystal energy landscape (i.e. those computed to be thermo-
dynamically feasible). The development of such computationally-
assisted crystal engineering strategies8,9 would move experi-
mental crystal form discovery beyond the traditional reliance
on empiricism and serendipity. Here we demonstrate how
computed crystal energy landscapes can be used in this
manner, speciﬁcally, to design a method for producing a
speciﬁc new polymorph (form Vw) of the anti-epileptic drug
carbamazepine (CBZ, Fig. 1).
CBZ has over 50 reported forms including 4
polymorphs.10–15 The structures of CBZ I, II, III and IV are
all based on a hydrogen-bonded dimer motif13 and despite
extensive experimental polymorph searches involving diverse
approaches,12,15–19 a pure catemeric form of this molecule has
never been reported. The strategy leading to the discovery
of CBZ V is based on the selection of an orthorhombic
polymorph (form II) of the CBZ analogue DHC20 (Fig. 1)
as a structural template for a predicted, though unobserved,
catemer-based form of CBZ (see ESI).12,21
In an eﬀort to obtain insights into the crystallization of
CBZ itself, an extended experimental and computational
investigation into physical form diversity in CBZ12,21 and the
related molecules DHC,22,23 CYH24 and CYT25 was carried
out. The computed lattice energy landscapes of each
molecule4,12,23 show that structures based on either hydrogen-
bonded dimer or catemer motifs are thermodynamically
feasible in every case. The experimental investigations, starting
from an automated solution crystallization screen, produced
several new polymorphs21–25 revealing close structural
relationships between the experimentally determined structures
shown in Fig. 2.
To further explore the isostructural relationships that
emerged, improved lattice energy calculations26 were carried
out in which the 4 molecules were substituted in turn into each
of the 8 distinct experimental lattices observed across the series
(Fig. 3, details in ESI). The simulated structure corresponding
to CBZ substituted in DHC II (i.e. CBZ V) is relatively low on
the lattice energy plot and comparable in stability with the
previously observed forms (Fig. 3).
As suggested by these calculations, CBZ V was successfully
obtained by templating growth of CBZ from the vapour phase
onto the surface of a DHC II crystal. 50 mg of CBZ III was
placed in a 10 mL glass vial and a single crystal of DHC II was
attached to a copper wire and suspended 1–2 cm above the
CBZ. The sealed vial was placed onto a hot-plate at 125 1C for
24–48 h. CBZ crystals formed by reverse sublimation onto the
surface of the seed and these crystals were removed and
identiﬁed by single-crystal X-ray diﬀraction. Crystals that
grew on the seed always formed on the smallest edge faces
of the crystal (Fig. 4) whilst those that grew on the wire or
Fig. 1 CBZ and the related molecules 10,11-dihydrocarbamazepine
(DHC), cyheptamide (CYH) and cytenamide (CYT).
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inside walls of the vial were either CBZ I or III. The crystal
structure of form V is catemeric (Fig. 5)z and is isostructural
with DHC II and the simulated CBZ structure (see ESI).
The formation of this speciﬁc CBZ polymorph, achieved
by combining experimental and computational studies of
polymorphic diversity in related molecules, has thus veriﬁed
the initial computational predictions that catemeric forms of
CBZ are feasible. Further work on this and other molecular
families is required to assess the general transferability of this
computationally-assisted approach to polymorph screening by
lattice energy calculations on isomorphous structures and to
deﬁne the templating mechanism in detail.
Form V CBZ represents a signiﬁcant advance in polymorph
discovery and control in that it did not result from the facile
extension of experimental crystallization search space for the
molecule, but rather by computer-aided exploration of the
polymorphs of related molecules to ﬁnd a template. This
approach of combining crystal energy landscape prediction,
experimental screening, and lattice energy substitution
calculations illustrates a strategy to increase the probability
that all practically important long-lived polymorphs are
discovered. In so doing, these methods oﬀer a new paradigm
in the control and selection of solid-state properties of pharma-
ceuticals and other speciality chemicals.
A predicted catemeric polymorph of CBZ has been
produced experimentally by exploiting the 3D similarity between
computed and experimental structures of closely related
molecules to ﬁnd a solid-state template. The fact that form
V CBZ has not been observed before, despite extensive
polymorph screening, emphasizes the need for caution in
concluding that unobserved thermodynamically feasible structures
cannot appear. In the case of CBZ at least, it would seem that
previous experimental searches provided insuﬃcient coverage
of the experimental crystallization space to allow the formation
of this polymorph.
The authors thank EPSRC for funding this work through
the Basic Technology program Control and Prediction of the
Organic Solid State (www.cposs.org.uk); Drs A. R. Kennedy
and Z. Gal for assistance with single-crystal diﬀraction data
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measured reﬂections = 5416, independent reﬂections = 2140, ymax =
67.96, Rint = 0.0624, 171 parameters, R = 0.045 (based on F and
1219 data with F2 4 2s(F2)), Rw = 0.1018 (based on F
2 and all 2140
unique reﬂections), S= 0.824. Orthorhombic, space group Pbca, unit
cell parameters a = 9.1245(5), b = 10.4518(5), c = 24.8224(11) A˚,
volume = 2367.2(2) A˚3; Z = 8, rc = 1.326 g cm
3, C15H12N2O,
Mr = 236.3.
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Fig. 2 Relationships between experimental forms of DHC, CYH,
CYT and CBZ. White and red labels correspond to catemer- and
dimer-based structures respectively; black arrows identify isostructural
relationships, including that between DHC II and CBZ V.
Fig. 3 Lattice energy substitution calculations for CBZ, CYT, CYH
and DHC in the 8 distinct crystal structure types observed experimentally
(Fig. 2). The colour of each symbol denotes the molecule (CBZ—yellow,
CYH—pink, CYT—green and DHC—grey) and the symbol represents
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lighted as an open box, with CBZ V in a double red box.
Fig. 4 DHC II seed crystal with thin plates of CBZ V (i–iii) emerging
from the edge faces.
Fig. 5 Single crystal structure of CBZ V showing the catemeric
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